18 F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma.
Emma KroezeLaura Arias PadillaBirgit BurkhardtAndishe AttarbaschiHannah von MersiRejin KebudiRutger A J NievelsteinNelleke TolboomMelanie M HagleitnerRoland P KuiperAuke BeishuizenJan L C LoeffenPublished in: Pediatric blood & cancer (2023)
18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.
Keyphrases
- pet ct
- positron emission tomography
- computed tomography
- end stage renal disease
- high resolution
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- bone marrow
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- emergency department
- magnetic resonance imaging
- squamous cell carcinoma
- radiation therapy
- bone mineral density
- postmenopausal women
- patient reported outcomes
- patient reported
- fluorescence imaging
- silver nanoparticles
- bone loss